• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Cardiology

Combination therapy of a monoclonal antibody and atorvastatin may help patients reach target LDL levels

bys25qthea
November 21, 2012
in Cardiology, Chronic Disease
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

Image: PD

Key study points: 

  1. A monoclonal antibody to PCKS9 (an enzyme that degrades LDL receptors) in combination with atorvastatin significantly reduced LDL after 8 weeks of use compared to atorvastatin alone.

Primer: Cardiovascular disease is one of the major causes of death in North America. One of the risk factors contributing to its increasing incidence is high cholesterol; specifically, a low-density lipid (LDL) level greater than 100 mg/dL is associated with an increased risk of heart disease.

As many North Americans are unable to meet this target with diet alone, many drugs have been developed to decrease the amount of LDL cholesterol within plasma. Statins, for example, have the potential of lowering LDL plasma levels by about 20 to 50%.

However, there is a small contingent of patients who still do not reach the recommended levels with statin therapy. An alternative therapeutic strategy might include targeting a protein called serum proprotein convertase subtilisin/kexin 9 (PCSK9). Its function is to bind to LDL receptors in tissues such as the liver and cause their degradation, which reduces the removal of LDL cholesterol from the blood stream.

The purpose of this phase 2 study was to determine whether SAR236553, an antibody that binds to PCSK9 and keeps it from interacting with the LDL receptor, in combination with atorvastatin, could decrease LDL levels in patients who could not reach target cholesterol levels.  

Background reading:  

RELATED REPORTS

Early exposure to allergenic foods may reduce incidence of long-term food allergy

Risk of post-vitrectomy endophthalmitis may have increased during the COVID-19 pandemic

Bosniak classification system differentiates benign renal cysts from cystic carcinoma [Classics Series]

  1. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials.
  2. Effect of a monoclonal antibody to PCSK9 on LDL cholesterol.

This [double-blind, phase II randomized controlled] study evaluated the use of high or low dose atorvastatin with SAR236553 vs. high dose atorvastatin with placebo. Patients received a subcutaneous shot of the monoclonal antibody or placebo every 2 weeks.

There was a significant reduction in plasma LDL from baseline when comparing the high dose atorvastatin plus the antibody vs. the control group (73.2% vs. 17.3%, p<0.001). This trend was also seen in other cholesterol measures such as Apolipoprotein B, non-HDL cholesterol and total cholesterol. All patients who used the monoclonal antibody achieved LDL < 100 mg/dL compared to 52% in the control group.

In sum: The authors showed that patients who used an antibody to a degrader of LDL-receptors in combination with atorvastatin had significantly greater reductions in LDL than patients who used atorvastatin alone.

Some limitations of this study include the small number of patients (~30 in each arm), the length of the study (8 weeks) and the exclusion of patients with diabetes and prior cardiovascular events. Furthermore, this study only measured decreases in LDL instead of hard endpoints like the number of cardiovascular events. The phase 3 trial would do well to further elucidate these points before we consider treating patients with the antibody.  

Click to read the study in NEJM 

By [JC] and [MP] 

© 2012 2minutemedicine.com. All rights reserved. No works may be reproduced without written consent from 2minutemedicine.com. Disclaimer: We present factual information directly from peer reviewed medical journals. No post should be construed as medical advice and is not intended as such by the authors or by 2minutemedicine.com. PLEASE SEE A HEALTHCARE PROVIDER IN YOUR AREA IF YOU SEEK MEDICAL ADVICE OF ANY SORT.  

Previous Post

[Physician Comment] Recurrent early Lyme disease is caused by reinfection, not relapse

Next Post

Cardiopulmonary exercise testing is safe for high-risk cardiovascular patients

RelatedReports

Peripregnancy nut consumption may decrease development of nut allergies
Chronic Disease

Early exposure to allergenic foods may reduce incidence of long-term food allergy

July 5, 2022
Masks for personal protection for SARS-CoV-2 infection
Ophthalmology

Risk of post-vitrectomy endophthalmitis may have increased during the COVID-19 pandemic

July 5, 2022
The ABCD2 score: Risk of stroke after Transient Ischemic Attack (TIA) [Classics Series]
Radiology Classics

Bosniak classification system differentiates benign renal cysts from cystic carcinoma [Classics Series]

July 5, 2022
Galcanezumab reduces the frequency of episodic cluster headaches
Chronic Disease

Cognitive behavioral therapy efficacious for treatment of comorbid posttraumatic headache and posttraumatic stress disorder symptoms among US veterans

July 4, 2022
Next Post

Cardiopulmonary exercise testing is safe for high-risk cardiovascular patients

Low molecular weight heparin most effective at reducing rate of venous thromboembolism in patients undergoing bariatric surgery

Increase in white matter hyperintensities seen in migraine patients

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Early exposure to allergenic foods may reduce incidence of long-term food allergy
  • Risk of post-vitrectomy endophthalmitis may have increased during the COVID-19 pandemic
  • Bosniak classification system differentiates benign renal cysts from cystic carcinoma [Classics Series]
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.